Abraxane在胃癌及卵巢癌中的应用

1、1会计学Abraxane在胃癌及卵巢癌中的应用在胃癌及卵巢癌中的应用晚期胃癌一线治疗III期临床研究紫杉醇联合卡培他滨序贯卡培他滨维持方案一线治疗晚期胃癌的开放、非对照、多中心临床研究紫杉醇卡培他滨卡培他滨4-6周期无进展直到进展或不能耐受毒性或撤出知情同意Cape1000mg/m2 bid d1-14PTX 80mg/m2 d1,8, Q3wCape1000mg/m2 bid d1-14DCR 80.9%随机1:1紫杉醇卡培他滨 顺铂卡培他滨4周期直到进展或6周期后结束治疗卡培他滨直到进展A组B组 晚期/复发胃或胃食管结合部腺癌 未接受过化疗，或经新辅助、辅助化疗结束超过6个月出现进展N=3

2、20Start Date: November 2009 Narikazu Boku, MDDivision of Gastrointestinal OncologyShizuoka Cancer Center, JapanGender: M / F27 / 9 Age, years: Median (range)62 (34 73) PS: 0 / 1 / 222 / 14 / 0Primary lesion: - / +23 / 13Target: 1st line failure23: Adjuvant failure13Prior regimen: S-117: S-1+CDDP11:

3、Xeloda+CDDP+Avastin 3: S-1+L-OHP 2: Others3Prior chemotherapy period, days: Median (range)175 (27 592)n = 36Treatment courseReasons for Discontinuation No. of Pts (%) 1:34 (100) 2:29(85) 3:22(65) 4:16(47) 5:10(29) 6:6(18) 7:6(18) 8:3(9) 9:3(9)10:1(3)11:1(3) No. of PtsDisease progression26Toxicity- C

4、reatinine increase1- DVT*1Pts refusal1ABI-007, 260mg/m2, q3w* DVT：深静脉血栓Progression Free Survival2008.3.18 monitoringOthers ( 3): WBC decrease, Lymphopenia, Hb decrease, ALP increase, Amylase increase2008.3.5 monitoringn=351: J Clin Oncol 17:319-323 (1999)2: ASCO 21 #600 (2002)3: ASCO 20044: Ann Onco

5、l 12:1133-1137 (2001)5: Gastric cancer 5:90-95 (2002) 6: ASCO 20037: Gastric cancer 9:14-8 (2006)8: Cancer Chemother Pharmacol9: ASCO 2007Teneriello M, et al. Presented at ASCO Annual Meeting 2007; Abstract 5525Teneriello M, et al. Presented at ASCO Annual Meeting 2007; Abstract 5525Teneriello M, et

6、 al. Presented at ASCO Annual Meeting 2007; Abstract 5525Teneriello M, et al. Presented at ASCO Annual Meeting 2007; Abstract 5525疗的周期数，最多治疗疗的周期数，最多治疗3周期周期n治疗达治疗达CR的患者，由经治医生决定是否再的患者，由经治医生决定是否再打两个周期。因此，打两个周期。因此，CR的患者可能接受最的患者可能接受最多多8个周期的化疗个周期的化疗Teneriello M, et al. Presented at ASCO Annual Meeting 200

7、7; Abstract 5525Teneriello M, et al. Presented at ASCO Annual Meeting 2007; Abstract 5525Teneriello M, et al. Presented at ASCO Annual Meeting 2007; Abstract 5525Teneriello M, et al. Presented at ASCO Annual Meeting 2007; Abstract 5525* RECIST测量标准：CR: 肿瘤完全消失PR: 肿瘤缩小50%SD: 肿瘤缩小50% 或 增大25% CA-125值测量标准

8、：CR: CA-125恢复至正常值范围PR: CA-125减少65%以上SD: CA-125减少低于65% 或 增加不超过40%治疗了46例患者，3度神经毒性的发生率是8.7%。Teneriello M, et al. Presented at ASCO Annual Meeting 2007; Abstract 5525Teneriello M, et al. Presented at ASCO Annual Meeting 2007; Abstract 5525Gender: M / F27 / 9 Age, years: Median (range)62 (34 73) PS: 0 / 1 / 222 / 14 / 0Primary lesion: - / +23 / 13Target: 1st line failure23: Adjuvant failure13Prior regimen: S-117: S-1+CDDP11: Xeloda+CDDP+Avastin 3: S-1+L-OHP 2: Others3Prior chemotherapy period, days: Median (range)175 (27 592)n = 362008.3.18 monitoringTenerie